{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:38:53Z","timestamp":1790127533580,"version":"4.0.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s10557-021-07242-7","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T10:03:54Z","timestamp":1629972234000},"page":"271-276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Neurocognitive Disorders Associated with PCSK9 Inhibitors: a Pharmacovigilance Disproportionality Analysis"],"prefix":"10.1007","volume":"37","author":[{"given":"Amandine","family":"Gouverneur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Sanchez-Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenaelle","family":"Veyrac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe-Elie","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"B\u00e9gaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2568-1928","authenticated-orcid":false,"given":"Julien","family":"Bezin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,26]]},"reference":[{"key":"7242_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388.","journal-title":"Eur Heart J"},{"key":"7242_CR2","doi-asserted-by":"publisher","first-page":"e1144","DOI":"10.1161\/CIR.0000000000000626","volume":"139","author":"PWF Wilson","year":"2019","unstructured":"Wilson PWF, Polonsky TS, Miedema MD, Khera A, Kosinski AS, Kuvin JT. Systematic Review for the 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1144\u201361.","journal-title":"Circulation"},{"key":"7242_CR3","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500\u20139.","journal-title":"N Engl J Med"},{"key":"7242_CR4","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489\u201399.","journal-title":"N Engl J Med"},{"key":"7242_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.pharmthera.2016.11.001","volume":"170","author":"M Banach","year":"2017","unstructured":"Banach M, Rizzo M, Nikolic D, Howard G, Howard Virginia J, Mikhailidis Dimitri P. Intensive LDL-cholesterol lowering therapy and neurocognitive function. Pharmacol Ther. 2017;170:181\u201391.","journal-title":"Pharmacol Ther"},{"key":"7242_CR6","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jacl.2018.05.012","volume":"12","author":"MR Mannarino","year":"2018","unstructured":"Mannarino MR, Sahebkar A, Bianconi V, Serban M-C, Banach M, Pirro M. PCSK9 and neurocognitive function: should it be still an issue after FOURIER and EBBINGHAUS results? J Clin Lipidol. 2018;12:1123\u201332.","journal-title":"J Clin Lipidol"},{"key":"7242_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25642","volume":"87","author":"DM Williams","year":"2020","unstructured":"Williams DM, Finan C, Schmidt AF, Burgess S, Hingorani AD. Lipid lowering and Alzheimer disease risk: a Mendelian randomization study. Ann Neurol. 2020;87:30\u20139.","journal-title":"Ann Neurol"},{"key":"7242_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10557-020-07045-2","volume":"35","author":"H Ying","year":"2021","unstructured":"Ying H, Wang J, Shen Z, Wang M, Zhou B. Impact of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering medicines on cognitive function: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2021;35:153\u201366.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7242_CR9","doi-asserted-by":"publisher","unstructured":"Guedeney P, Giustino G, Sorrentino S, Claessen BE, Camaj A, Kalkman DN, Vogel B, Sartori S, De Rosa S, Baber U, Indolfi C, Montalescot G, Dangas GD, Rosenson RS, Pocock SJ, Mehran R (2019) Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J.\u00a0https:\/\/doi.org\/10.1093\/eurheartj\/ehz430","DOI":"10.1093\/eurheartj\/ehz430"},{"key":"7242_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7242_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2165\/00002018-200225060-00002","volume":"25","author":"A Bate","year":"2002","unstructured":"Bate A, Lindquist M, Edwards IR, Orre R. A data mining approach for signal detection and analysis. Drug Saf. 2002;25:393\u20137.","journal-title":"Drug Saf"},{"key":"7242_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40264-020-01021-3","volume":"44","author":"G di Mauro","year":"2021","unstructured":"di Mauro G, Zinzi A, Scavone C, Mascolo A, Gaio M, Sportiello L, et al. PCSK9 inhibitors and neurocognitive adverse drug reactions: analysis of individual case safety reports from the Eudravigilance Database. Drug Saf. 2021;44:337\u201349.","journal-title":"Drug Saf"},{"key":"7242_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s40264-015-0296-6","volume":"38","author":"KJ Swiger","year":"2015","unstructured":"Swiger KJ, Martin SS. PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA Directive and a proposal for N-of-1 trials. Drug Saf. 2015;38:519\u201326.","journal-title":"Drug Saf"},{"key":"7242_CR14","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3389\/fnins.2020.00609","volume":"14","author":"EM O\u2019Connell","year":"2020","unstructured":"O\u2019Connell EM, Lohoff FW. proprotein convertase subtilisin\/kexin type 9 (PCSK9) in the brain and relevance for neuropsychiatric disorders. Front Neurosci. 2020;14:609.","journal-title":"Front Neurosci"},{"key":"7242_CR15","doi-asserted-by":"crossref","unstructured":"Picard C, Poirier A, B\u00e9langer S, Labont\u00e9 A, Auld D, Poirier J, et al. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) in Alzheimer\u2019s disease: a genetic and proteomic multi-cohort study. Lakshmana MK, editor. PloS One. 2019;14:e0220254.","DOI":"10.1371\/journal.pone.0220254"},{"key":"7242_CR16","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1161\/CIRCULATIONAHA.117.029785","volume":"137","author":"MT Mefford","year":"2018","unstructured":"Mefford MT, Rosenson RS, Cushman M, Farkouh ME, McClure LA, Wadley VG, et al. PCSK9 variants, LDL-cholesterol, and neurocognitive impairment: the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Circulation. 2018;137:1260\u20139.","journal-title":"Circulation"},{"key":"7242_CR17","doi-asserted-by":"crossref","unstructured":"Paquette M, Saavedra YGL, Poirier J, Th\u00e9roux L, Dea D, Baass A, et al. Loss-of-function PCSK9 mutations are not associated with Alzheimer disease. J Geriatr Psychiatry Neurol. SAGE Publications Inc STM; 2018;31:90\u20136.","DOI":"10.1177\/0891988718764330"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07242-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-021-07242-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07242-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T16:05:38Z","timestamp":1678809938000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-021-07242-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,26]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["7242"],"URL":"https:\/\/doi.org\/10.1007\/s10557-021-07242-7","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,26]]},"assertion":[{"value":"16 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}